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Editorial on the Research Topic
Current Challenges in Cardioembolic Stroke
Cardioembolism is one of the most frequent causes of ischemic stroke, accounting for at least
20% of all ischemic strokes. Moreover, cardioembolic stroke entails higher severity and poorer
outcome compared to other etiologies. Atrial fibrillation is the most frequent underlying disease,
although several other cardiac disorders such as ventricular akinesia, valvular heart disease, acute
myocardial infarction, endocarditis, monogenic diseases with cardiac involvement, or complicated
interventional cardiac procedures can also be involved in the development of cardioembolic stroke.
Direct oral anticoagulants have revolutionized stroke prevention in patients suffering from atrial
fibrillation, however, more knowledge is needed regarding the long-term outcomes in patients
treated with these drugs.
In recent years, much attention has been paid to the search for hidden cardioembolic sources
for ischemic stroke, and the “embolic stroke of unknown source” (ESUS) concept was raised to
improve the detection of occult embolic diseases, mainly paroxysmal atrial fibrillation. However,
the failure of direct oral anticoagulants in recent clinical trials with patients diagnosed with ESUS
has raised concerns regarding the appropriateness of a low-intensity diagnostic workup and points
to the return of the diagnostic concept of cryptogenic stroke. This highlights the need to increase
the search for potential hidden etiologies through advanced diagnostic procedures.
This Research Topic issue provides an up-to-date collection of manuscripts focused on the
challenge of diagnosis and management of cardioembolic strokes.
The role of echocardiography is reviewed by Pagola et al. highlighting the potential application
of Point of Care UltraSound (POCUS) as a helpful screening method at the Stroke Unit.
Furthermore, Arnold et al. provide a comprehensive review on the most promising biomarkers
for the diagnosis of cardioembolic stroke, including blood-based, genomic, transcriptomic,
metabolic, electrocardiographical, echocardiographical, and advance cardiac imaging biomarkers.
They discuss the existing evidence for possible clinical applications in risk stratification and in
accelerating etiological classification as well as optimal management, from a perspective of the
forthcoming implementation of personalized medicine in stroke management.
The importance of atherosclerotic plaques in the aortic arch as a potential cause of embolic
stroke has been underestimated in the majority of the etiological classifications of stroke,
being relegated in most of them to stroke of undetermined origin, mainly because of a clear
recommendation for its systematic search in the stroke patients has not been established. The
narrative review by Viedma-Guiard et al. provides an excellent and up-to-date overview of the
role of aortic sources of embolism in ischemic stroke, focusing on the diagnostic challenges and the
current evidence for the optimal treatment in stroke prevention.
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Recently the ESUS concept has been called into question. This
concept was proposed in 2014 by the Cryptogenic Stroke/ESUS
InternationalWorkingGroup under the rationale of the common
underlying thromboembolism mechanism in the group of
patients with non-lacunar ischemic strokes in which the basic
diagnostic approach did not found any undoubtable cause for
the stroke. This concept included minor-risk or covert cardiac
sources (such as covert paroxysmal atrial fibrillation), paradoxical
embolism and non-occlusive atherosclerotic plaques in the aortic
arch, cervical or intracranial arteries (1). However, as long as
this concept was implemented in clinical practice, it has been
clear that the majority of stroke patients classified as ESUS
are more similar to atherosclerotic stroke patients in their
clinical features and that non-occlusive atherosclerotic plaques
might be the most common source of embolism in those cases.
The manuscript by Wan et al. also provides new data on
this atherosclerotic-lookalike clinical profile in a prospectively
collected series of 119 acute ischemic stroke patients. To
deepen the current controversy surrounding the ESUS concept,
Fuentes et al. list several arguments against the use of the
ESUS concept in clinical practice, advising stroke physicians
to be smart in the search for underlying causes of ischemic
stroke, optimizing advanced diagnostic procedures according
to the patient’s and stroke’s characteristics, attempting to find
the correct diagnosis for stroke patients and reducing rates of
cryptogenic stroke diagnosis.
In the field of stroke prevention in cardioembolic strokes, this
Research Topic issue includes two interesting manuscripts. The
prospective multicentre RESTAIC Registry by Gutiérrez-Zúñiga
et al. explored the differences in ischemic and haemorrhagic
events when using oral anticoagulation for secondary stroke
prevention according to the type of anticoagulant treatment
(vitamin K antagonists or direct oral anticoagulant drugs)
showing a low frequency of bleeding complications, with no
significant differences between anticoagulant drugs at long-
term follow-up (of up to 3 years from a stroke). Besides,
they provide new insights on the main reasons for switching
oral anticoagulant drugs in clinical practice, being the majority
of them due to stroke recurrences and labile INR. The
other manuscript on stroke prevention is the protocol for
LASER (Lixiana Acute Stroke Evaluation Registry) a randomized
clinical trial and an associated registry of early anticoagulation
with edoxaban after ischemic stroke in patients with atrial
fibrillation. It is aimed at recruiting 150 patients with ischemic
stroke and atrial fibrillation who will be randomized within 5
days of stroke onset to early or delayed edoxaban initiation
(Alrohimi et al.).
Finally, this issue also includes a case report by Sarti et al.
highlighting the relevance of atrial appendage morphology on
patients with atrial fibrillation and resistant stroke despite
adequate anticoagulant therapy.
We would like to thank all the contributing authors for their
manuscripts in this challenging time in which the COVID-
19 pandemic has severely impacted stroke care and research,
limiting the number of the expected manuscripts for this
Research Topic issue. We hope that the pandemic will soon
disappear, and we can refocus all our efforts on fighting stroke,
one of the leading causes of death and the first cause of
disability worldwide.
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